https://doi.org/10.48047/AFJBS.6.8.2024.128-140

African Journal of Biological Sciences

Research Paper Open Access

TRANSLATIONAL IMPLICATIONS OF NEURONAL DOPAMINE D3 RECEPTORS FOR PRECLINICAL RESEARCH AND CNS DISORDERS

Shweta Bhandari[1], Bharti Chauhan[2], Nakul Gupta[3], Ankita Tripath[4], Subhashish Tripsthy[5], Anoop Kumar Panday[6], Kumar Gaurav[7], Debashis Purohit, Sajeeda Niketh[9]*, Keshamma E[10], Suraj Mandal[11]

[1]*Assistant Professor, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat,391760*

[2]*Assistant Professor, IIMT College of Pharmacy, Greater Noida, UP*

[3]*Director & Professor, IIMT College of Pharmacy, Greater Noida, UP*

[4]*Associate Professor, IIMT College of Pharmacy, Greater Noida, UP*

[5]*Professor, BMS College of Pharmacy, Amethi, Tiloi, pin229309*

[6]*Assistant Professor, Maharana Pratap Engineering College, Kothi, Mandhna, Kanpur, Uttar Pradesh, Pin code- 209217*

[7]*Assistant professor, Graphic Era Hill University Dehradun, 566/6 Bell Road Society Area, Clement Town, Dehradun, Bharu Wala Grant, Uttarakhand, 248002*

[8]*Research Scholar, School of Health and Allied Sciences, Career Point University, Alaniya, Kota, Rajasthan, Pin- 324005*

[9]*Department of chemistry and Biochemistry, Nrupathunga University, Bengaluru – 560001, Karnataka, India.*

[10]*Associate professor, Department of Biochemistry, Maharani Cluster University, Bengaluru-560001, Karnataka, India.*

[11]*Assistant Professor, Department of Pharmacy, IIMT College of Medical Sciences, IIMT University, O-Pocket, Ganganagar, Meerut, 250001, U.P., India*

Corresponding Author Details:

Dr. Sajeeda Niketh

Associate Professor, Department of Chemistry and Biochemistry, Nrupathunga University, Nrupathunga Road, Bengaluru-560001

sajeedaniketh@gmail.com

Article History

Volume 6,Issue 8, 2024

Received:19 Feb 2024

Accepted : 29 Mar 2024

doi: 10.33472/AFJBS.6.8.2024.128-140

Abstract

The dopamine (DA) D3 receptor (D3R) regulates motor function, behavior that is rewarding and motivating, and cognitive processes. As indicated by ongoing investigations, the D3R controls neuronal turn of events, empowers primary versatility, and starts neuroprotective intracellular exercises. The CNS and fringe conveyance, synthetic cosmetics, and cell flagging pathways of the dopamine D3 receptor (D3R), which was cloned a long time back, have all been very much examined. CNS capabilities like award, learning, engine control, feeling guideline, and social way of behaving are undeniably interceded by D3Rs. High proclivity ligands, like particular agonists, halfway agonists, and bad guys, have been looked for to more readily comprehend the jobs of D3Rs, which are fascinating restorative targets. Drug-like atoms with high fondness, selectivity, and usefulness for D3Rs have been sought after with expectations of treating CNS ailments, for example, sorrow, Parkinson's illness, schizophrenia, drug abuse, and a tendency to fidget. The translational implications of pharmacological breakthroughs related to D3R for preclinical research and possible human therapy are examined in this work. In order to improve our knowledge of and ability to treat CNS illnesses, it addresses the necessity for highly functional and selective ligands that target D3Rs.

Keywords: *Translational Implications, Dopamine D3 Receptors, CNS Disorders, Dopamine D_3 Functions.*

1. INTRODUCTION

Jean-Charles Schwartz, Pierre Sokoloff, and partners found D3R subtypes in 1990. D3Rs were promptly concentrated on in Parkinson's sickness (PD) to decide what they meant for the advantages and disadvantages of DA substitution treatment, which incorporates L-dopa or DAR agonists [1]. Today, drug fixation, misery, anxious legs condition, and schizophrenia might target them [2]. They are for the most part utilized for preclinical information in many diseases [3]. A few contemporary antipsychotics target and repress D3R, as is notable [4].

Engine side effects of Parkinson's sickness (PD) incorporate bradykinesia, unbending nature, postural precariousness, and resting quake [5]. Numerous non-engine side effects are not recorded in the clinical portrayal [6]. Degeneration of dopamine (DA) neurons in the substantia nigra (SN), which innervates the striatum, may have changed the basal ganglia (BG), an assortment of subcortical designs that manage engine conduct and cause engine side effects [7]. DA neuron degeneration starts gradually before side effects manifest and creates at various rates after conclusion, contingent upon the sickness [8]. Parkinson's sickness additionally causes noradrenergic, serotonergic, and mesencephalic cholinergic neuron changes to variable degrees [9]. Harm to these frameworks is anticipated to influence anew patients' clinical results and the infection's medicines' advantages and disadvantages.

Since its revelation in the mid-1990s, pharmacologists have concentrated on the dopamine (DA) D3 receptor. Curiously, and oftentimes without remembering it, antiparkinsonian prescriptions like L-dopa and DA agonists, as well as unselective antipsychotics like haloperidol and chlorpromazine, designated the D3 receptor before its revelation [10]. These mixtures have

significant fondness for both D2/D3 receptors, yet their principal objective was to inspire post-synaptic D2-like pharmacologic activities [11]. Because of their gentle consequences for engine capability, D3 receptors were remembered to have minimal restorative use [12]. D3 receptor pharmacology varied fundamentally from D2 receptor pharmacology, recommending a helpful capability for D3 focusing on [13]. These discoveries were upheld by D3 receptor cloning, specific or D3-particular compound ID and portrayal, and upgraded D3 receptor science information [14]. Indeed, even after broad drug and scholastic review, there is no specific D3 agonist or bad guy for human utilization [15]. The 157 exceptional D3 adversary licenses enrolled somewhere in the range of 2008 and 2012 exhibit this contribution. These prescriptions are generally regularly utilized for liquor abuse, substance abuse, schizophrenia, Parkinson's sickness, smoking end, diabetic kidney harm, and untimely discharge [16]. Flow research recommends a job in state of mind and cognizance. Luckily, the pharmacopeia has a few non-specific "particular" D3 specialists. These synthetic substances can be utilized to concentrate on human D3-subordinate pharmacology when dosed appropriately. Many accept that a drug is "special" for a receptor in the event that it ties to it in vitro with multiple times the partiality of the second-best objective. The original of ergot-determined DA agonists had comparable in vitro proclivity for D2 and D3 receptors, yet the subsequent age had a higher liking for D3. This model predicts that D3-particular meds could tie specially to D3 receptors at low successful dosages, causing explicit pharmacodynamic impacts.

1.1. Objectives of the study

- To examined the translational implications of pharmacological breakthroughs related to D3R for preclinical research and possible human therapy.
- To improve our knowledge of and ability to treat CNS disorders, it addresses the necessity for highly functional and selective ligands that target D3Rs.

2. LITERATURE REVIEW

E. M. Pich (2015) suggested that the slowing of sickness in Parkinson's illness patients treated with dopamine agonists could be expected, to a limited extent, to a clever brain adaptability job of the D3 receptor corresponding to dendritic arborization outgrowth in dopaminergic neurons. The energizer like impacts seen with DA agonists when utilized related to norm of care might be because of comparable cycles. Late proof suggests a potential connection between hyperactive D3 receptors and serious unfavorable occasions (i.e., motivation control disorders) in people who are now helpless to taking enemy of parkinsonian DA agonists [17]. Repositioning buspirone, an anxiolytic drug with D3-particular antagonistic highlights, or using novel specific D3 antagonists or halfway agonists as of now being produced for schizophrenia might actually accomplish the goal of blocking D3 receptors as a treatment for habit-forming disorders. With promising preclinical proof for a cognitive upgrade impact, ABT-925 is as of now the just specific D3 antagonist undergoing Stage II testing in patients with schizophrenia. To wrap things up, primer pharmacogenetic studies have shown that ABT-925 may work in a patients because of a D3 receptor variety, which could prompt a more fitted way to deal with medical care.

Yang, P. (2021) analyzed the association between's dopamine receptors and clinical appearances of Parkinson's disease (PD), as well as to quantitatively choose the particular densities of dopamine D1 receptors (D1R), D2R, and D3R in charge, Alzheimer's disorder (Advancement), and Lewy body affliction (LBD) patients (including PD, Dementia with Lewy bodies, and Parkinson's contamination dementia) [18]. Using one more quantitative autoradiography strategy that we had grown previously, they broke down the D1R, D2R, and D3R densities in the striatum and substantia nigra (SN). Likewise, we used in situ hybridization to investigate striatal D2R and D3R mRNA explanation. While there were no significant changes in striatal D1R levels among the groups, the data showed that PD patients' striatums had significantly lower D2R levels than the control and Advancement groups. There was a stronger association between the joined striatal D1R and D3R densities and a couple of clinical incidental effects, for instance, the age of beginning, PD stage, dopamine responsiveness, and perseverance time subsequent to beginning, than between the two alone. By detecting D1R + D3R, rather than just dopamine D1 or D3 receptors, we might have the choice to reason the outcomes in PD diagnosis, treatment, and prognosis. This is particularly the circumstance while dealing with additional carefully prepared individuals who normally show decreased D2R enunciation due to this disorder.

Karthivashan (2020) investigated the two essential treatment targets for PD, whether it's idiopathic or indicative, are DA and its antecedent, levodopa (l-dopa). Regardless of 10 years of examination into likely medicines for Parkinson's sickness, nobody has had the option to figure out how to stop the infection's progression [19]. Issues with bioavailability and unfortunate blood-cerebrum obstruction sidestep have even plagued DA substitution treatment, a viable PD treatment approach that provisions an outer wellspring of DA or l-dopa. Nonetheless, various drug conveyance frameworks have been made to evade the hindrances associated with CNS treatments, because of ongoing headways in nanotechnology. Here, we planned to detail the present status of PD prescriptions, explicitly DA substitution treatments, and the custom fitted lipid-based nanodrug conveyance frameworks that are utilized around here. This work begins by discussing the historical backdrop of Parkinson's illness (PD), then, at that point, continues on to portray the latest sub-atomic targets, the meds and limits that are right now utilized in clinical practice, different lipid-based PD nanotherapeutics, functionalized nanoparticles, and the specialized parts of cerebrum conveyance. It finishes up by looking forward to future prospects that could work on the utilization of nanotherapeutics in the treatment of PD.

Sokoloff (2017) researched in various creature models, D3 receptor antagonists worked on cognitive capability and checked the social impacts of blocking NMDA receptors. The negative outcomes from the clinical preliminaries of two D3 receptor-specific drugs in schizophrenia have all the earmarks of being credited to deficient target engagement; the results with a third particle, F17464, have not been uncovered at this point. There is mounting proof that D3 receptors don't regulate the reinforcing impacts of habit-forming drugs (beside liquor under low interest), yet they truly do impact the high interest inspiration to consume the medications, the reactivity to signs related with drugs, and the drug-seeking ways of behaving actuated by backslide related boosts in people [20]. A few kinds of drug fixation are related with raised D3 receptor articulation in PET-

estimated human subjects. Subsequent to quitting smoking for the evening, a single portion of GSK598809, a D3 receptor-selective antagonist, briefly diminished cravings in grown-ups. Beginning assessment of target engagement using PET will help with the clinical advancement of D3-specific drugs.

3. STRUCTURE OF DOPAMINE D3R

The G-protein coupled receptor family (GPCR) consolidates the D3R. The transmembrane space of class A, the biggest extraordinary class of GPCRs, is the sole part lacking a significant extracellular space. It is made from amino and carboxyl finishes. The transmembrane region, which is contained seven transmembrane helices embedded in the cell layer and coupled by three extracellular and three intracellular circles, is straightforwardly restricted by nearby ligands of aminergic GPCRs. The eighth short α-helix (H8) is the protein's C-end.

Two described elective splicing-created isoforms of human D3R and one computationally planned putative isoform are accessible in the UniProt data set. The most widely recognized isoform has a lengthy ICL3 region and is 400 amino acids long. By and by, various other then again joined variations that don't tie dopamine (DA) have likewise been accounted for in a few animal categories and are thought to work by controlling receptor dimerization.

Arrangement study shows that inside the D2-like subgroup of the DA receptor subfamily, the D3R is more like the D2R (around 55% personality) than the D4R (roughly 40% character) (Table 1).

Table 1: The percentage personality framework that Clustal2 generated for D2-like receptors in a few animal categories. software; r = rat; m = mouse; h = human.

Name	UniProt ID	rD3R	hD4R	hD3R	mD3R	hD2R
hD4R	P21917-1	39.8	99.8	40.5	39.6	38.2
mD3R (long)	P30728-1	96.9	39.6	90.3	99.9	54.0
hD3R	P35462-1	88.9	40.5	99.8	90.2	58.3
hD2R (long)	P14416-1	54.3	38.7	58.3	54.3	99.9
rD3R	P19020-1	100	40.5	89.2	97.0	54.0



Figure 1: The percentage personality framework that Clustal2 generated for D2-like receptors in a few animal categories. software; r = rat; m = mouse; h = human.

The circle segments, especially the IL3 somewhere in the range of TM5 and TM6, are where most of the varieties in D2-like receptor successions might be noticed. Remember that this circle is somewhere else where the D2R or D3R short and long isoforms diverge.

The sole 3D model of hD3R that has been tentatively recorded so far is in a conformational state where the receptor is latent while contacting an antagonist, for example, eticlopride. That, yet the GPCRdb has a homology model of the dynamic compliance of the hD3R, with the 5-HT1B receptor structure serving as the significant format. Furthermore, other D2R-like receptors' as of late revealed X-beam and cryo-EM designs might act as important layouts for homology modeling. The expected application ought to guide the determination of the format. For instance, the D3R structure that contains eticlopride is dynamic, however the latent state addressed by the risperidone-bound D2R structure is unique. The D2R structure bound to bromocriptine is likewise in a functioning complex with the G-protein.



Figure 2: The hD3R structure, which consolidates the docked regular ligand (DA) into the D3R precious stone construction

4. BEHAVIORAL FUNCTIONS OF THE D3RS

Contribution of the D3R-framework in the regulation of locomotor, cognitive, social, close to home, and persuasive exercises is generally acknowledged. With an eye on reviewing D3R's behavioral pharmacology in relation to movement, social-emotional behavior, and cognition, this part tries.

4.1. Importance for Cognitive Processes

Cognitive deficiencies can be enhanced in creature models by intensifies that are either full antagonists or D3R preferring fractional agonists. Instances of such mixtures incorporate BP-897, cariprazine, or its metabolite, didesmethyl-cariprazine (Table 2). Since cariprazine helped cognition in schizophrenia patients — an impact not frequently found in antipsychotics — this favorable to cognitive action probably works in individuals also. In people, ABT-925 epitomizes supportive of cognitive adequacy; the sole explicit D3R antagonist has progressed to clinical testing for schizophrenia. ABT-925 neglected to accomplish its principal goal of improving chief capability (a verbal recognition memory task), although it gave indications of progress in feeling recognition and a subset of patients.

Table 2: Cognitive impacts of fractional agonists that favor D3R

Compound	Social Measure	Impairing Agent	Species	Impact
BP-897	water maze	FG-7142; scopolamine	rat	+
cariprazine	social recognition memory	PCP	mouse	+
	novel item recognition	neonatal PCP, social isolation	rat	+
	novel item recognition	delay	rat	+
	operant inversion learning	PCP	rat	+
	T-labyrinth	PCP	mouse	+
	5-decision sequential response time test	PCP	rat	+
	water maze	scopolamine	rat	+
	attentional set-shifting	PCP	mouse	+
	novel item recognition	PCP	rat	+



Figure 3: Cognitive impacts of fractional agonists that favor D3R

In D3R receptor knockout mice, the significance of D3R antagonism in cognition is well demonstrated. Compounds like buspirone or cariprazine, which include a D3R component in their chemical profile, are unable to repair the cognitive deficits generated by MK-801 or PCP. Similarly, D3R deletion mice were unable to recover from a cognitive loss caused by MK-801. This was also observed when using the D3R antagonist Y-QA31. Genetically induced loss of D3Rs improves cognition in a manner analogous to systemic administration of D3R antagonists, with enhanced activation of cortical neurons and elevated levels of DA in the striatum and accumbal areas. Mice can also avoid the loss of spatial memory that comes with getting older if they don't have D3R. Heterozygous deletion of the dysbindin-1 gene impairs working memory, whereas D3R hypofunction in conjunction with decreased dysbindin-1 production restores normal functioning of the gene. Chourbaji et al. found no changes to working memory function on the T-maze when mice were tested under this condition, so not all reports support the idea that knocking off the D3R has a positive effect on cognition. However, contrary to what one might assume from research with D3R agonists, an overabundance of D3Rs restricted to the striatum disturbs motivation rather than causing cognitive impairments in mice.

4.2. Role in Profound Regulation

The exact capability of D3Rs in the regulation of feelings (tension, inspiration, and social pressure reactivity) is comparatively minimal perceived for what it's worth on account of locomotor way of behaving (Table 3). There is conflicting information from investigations of D3R knockout mice on the job of D3Rs in feeling regulation. Some exploration found lower levels of uneasiness or burdensome like ways of behaving in these mice, while others tracked down higher levels.

Table 3: The effect of D3R ligands on tension, amnesia, and stress reactivity on conduct

Compound	Behavioral Assay	Impairing Agent	Species	Effect
nafadotride	four plate	-	mouse	Ø
	struggle drinking (Vogel)	-	rat	+

U99194	raised in addition to labyrinth	-	rat	+
	open field	chronic WIN55,212–2	rat	Ø
	light-dim box	-	rat	+
	four plate	-	mouse	+
	struggle drinking (Vogel)	-	rat	+
7-OH-DPAT	raised in addition to labyrinth	-	mouse	+
	struggle drinking (Vogel)	-	rat	+
	tail suspension	-	mouse	+
	constrained swimming	-	rat	+
BP-897	constrained swimming	-	rat	Ø
	struggle drinking (Vogel)	-	rat	+



Figure 4: The effect of D3R ligands on tension, amnesia, and stress reactivity on conduct

Data regarding the counter anhedonic or anxiolytic impacts of D3R ligands is restricted and conflicting in the writing. Nafadotride and U99194, two prototypical D3R preferring antagonists with D2 receptorial exercises, prompted anxiolysis-like impacts in creature models. U99194 microinjected into the basolateral amygdala diminished restless way of behaving, but fundamental organization of a similar synthetic neglected to lighten uneasiness in teenage rodents exposed to diligent weed openness.

An increasingly clear image of the conduct influences is emerging from the information on D3R agonists and fractional agonists. In various creature and recreated models, D3R agonists such 7-OH DPAT, ropinirole, and U99194 showed anxiolytic and energizer like impacts. Essentially, BP-897, a D3R fractional agonist, had no impact in the constrained swimming test however created anxiolytic-like results in the Vogel rebuffed drinking and raised in addition to labyrinth tests.

4.3. Role in Social Behavior

Inhibiting the D3R enhances social recognition memory, according to a number of researches summarised in Table 2. Table 4 shows that D3Rs appear to regulate various parts of social behaviour in addition to their impact on memory components of social behaviour. Research has demonstrated that D3R agonists, when given systemically, can decrease huddling behaviour in rats and social interaction in mice. If administered topically to the lateral septum, D3R agonists may not always impair social behaviour. An important step in developing new drugs, the ABT-127 induced suppression of huddling helped find the D3R antagonist A-690344, which prevented the agonist's negative effects on huddling. In mice, the D3 agonist7-Gracious DPAT mitigates the impacts of PCP on friendly cooperation shortages, though U99194 reestablishes these shortfalls. Subacute social collaboration shortages in mice generated by ABT-925can be switched by the D3R explicit antagonist F17141. In a creature model of mental imbalance delivered by pre-birth valproate openness, the social lack was checked by the D3R full antagonist F17464. In creature models of schizophrenia, the D3R fractional agonist cariprazine can assist with improving social collaborations.

Table 4: The influence of D3 ligands on social behavior

Compound	Social Test	Impairing Agent	Species	Impact
cariprazine	social cooperation	PCP	mouse	+
	social cooperation	PCP	rat	+
	social cooperation	neonatal PCP, social isolation	rat	+
ABT-925	huddling	PD-128907	rat	+
U99194	social cooperation	PCP	mouse	+
	social cooperation	-	mouse	+
ABT-127	huddling	PD-128907	rat	+
F17141	social cooperation	MK-801	mouse	+
A-690344	huddling	PD-128907	rat	+



Figure 5: The influence of D3 ligands on social behavior

5. CONCLUSION

The dopamine D3 receptor, often known as the D3R, is a prospective target for pharmacological therapies in a variety of illnesses that affect the central nervous system. In order to create effective therapeutic techniques, it is essential to have a solid understanding of its distribution, molecular structure, signalling pathways, and behavioural activities. The development of particular agonists or antagonists for human usage has not yet taken place, despite the fact that research is now being conducted with the objective of locating ligands with high affinity and selectiveity for D3 receptors. On the other hand, drugs that have a D3R affinity are now being investigated for the possible therapeutic effects they could have in the treatment of illnesses such as schizophrenia, depression, Parkinson's disease, substance misuse, and behaviour disorders that include impulse control. It is necessary to do additional research in order to unravel the specific processes of D3R modulation and to create treatments that are therapeutically viable for these devastating illnesses of the central nervous system.

REFERENCES

1. *Mandal S, Vishvakarma P. Nanoemulgel: A Smarter Topical Lipidic Emulsion-based Nanocarrier. Indian J of Pharmaceutical Education and Research. 2023;57(3s):s481-s498.*
2. *Mandal S, Jaiswal DV, Shiva K. A review on marketed Carica papaya leaf extract (CPLE) supplements for the treatment of dengue fever with thrombocytopenia and its drawback. International Journal of Pharmaceutical Research. 2020 Jul;12(3).*
3. *Mandal S, Bhumika K, Kumar M, Hak J, Vishvakarma P, Sharma UK. A Novel Approach on Micro Sponges Drug Delivery System: Method of Preparations, Application, and its*

Future Prospective. Indian J of Pharmaceutical Education and Research. 2024;58(1):45-63.

4. *Mishra, N., Alagusundaram, M., Sinha, A., Jain, A. V., Kenia, H., Mandal, S., & Sharma, M. (2024). Analytical Method, Development and Validation for Evaluating Repaglinide Efficacy in Type Ii Diabetes Mellitus Management: a Pharmaceutical Perspective. Community Practitioner, 21(2), 29–37. https://doi.org/10.5281/zenodo.10642768*
5. *Singh, M., Aparna, T. N., Vasanthi, S., Mandal, S., Nemade, L. S., Bali, S., & Kar, N. R. (2024). Enhancement and Evaluation of Soursop (Annona Muricata L.) Leaf Extract in Nanoemulgel: a Comprehensive Study Investigating Its Optimized Formulation and Anti-Acne Potential Against Propionibacterium Acnes, Staphylococcus Aureus, and Staphylococcus Epidermidis Bacteria. Community Practitioner, 21(1), 102–115. https://doi.org/10.5281/zenodo.10570746*
6. *Khalilullah, H., Balan, P., Jain, A. V., & Mandal, S. (n.d.). EUPATORIUM REBAUDIANUM BERTONI (STEVIA): INVESTIGATING ITS ANTI-INFLAMMATORY POTENTIAL VIA CYCLOOXYGENASE AND LIPOOXYGENASE ENZYME INHIBITION - A COMPREHENSIVE MOLECULAR DOCKING AND ADMET. Community Practitioner, 21(03), 118–128. https://doi.org/10.5281/zenodo.10811642*
7. *Mandal, S. (n.d.). GENTAMICIN SULPHATE BASED OPHTHALMIC NANOEMULGEL : FORMULATION AND EVALUATION , UNRAVELLING A PARADIGM SHIFT IN NOVEL PHARMACEUTICAL DELIVERY SYSTEMS. Community Practitioner, 21(03). https://doi.org/10.5281/zenodo.10811540*
8. *Mandal, S., Tyagi, P., Jain, A. V., & Yadav, P. (n.d.). Advanced Formulation and Comprehensive Pharmacological Evaluation of a Novel Topical Drug Delivery System for the Management and Therapeutic Intervention of Tinea Cruris (Jock Itch). Journal of Nursing, 71(03). https://doi.org/10.5281/zenodo.10811676*
9. *Mishra, N., Alagusundaram, M., Sinha, A., Jain, A. V., Kenia, H., Mandal, S., & Sharma, M. (2024). Analytical Method, Development and Validation for Evaluating Repaglinide Efficacy in Type Ii Diabetes Mellitus Management: a Pharmaceutical Perspective. Community Practitioner, 21(2), 29–37. https://doi.org/10.5281/zenodo.10642768*
10. *Singh, M., Aparna, T. N., Vasanthi, S., Mandal, S., Nemade, L. S., Bali, S., & Kar, N. R. (2024). Enhancement and Evaluation of Soursop (Annona Muricata L.) Leaf Extract in Nanoemulgel: a Comprehensive Study Investigating Its Optimized Formulation and Anti-Acne Potential Against Propionibacterium Acnes, Staphylococcus Aureus, and Staphylococcus Epidermidis Bacteria. Community Practitioner, 21(1), 102–115. https://doi.org/10.5281/zenodo.10570746*
11. *Pal N, Mandal S, Shiva K, Kumar B. Pharmacognostical, Phytochemical and Pharmacological Evaluation of Mallotus philippensis. Journal of Drug Delivery and Therapeutics. 2022 Sep 20;12(5):175-81.Micheli, F., & Heidbreder, C. (2013). Dopamine D3 receptor antagonists: a patent review (2007–2012). Expert opinion on therapeutic patents, 23(3), 363-381.*

12. *Mugnaini, M., Iavarone, L., Cavallini, P., Griffante, C., Oliosi, B., Savoia, C., ... & Bani, M. (2013). Occupancy of brain dopamine D3 receptors and drug craving: a translational approach. Neuropsychopharmacology, 38(2), 302-312.*

13. *Nakajima, S., Gerretsen, P., Takeuchi, H., Caravaggio, F., Chow, T., Le Foll, B., ... & Graff-Guerrero, A. (2013). The potential role of dopamine D3 receptor neurotransmission in cognition. European Neuropsychopharmacology, 23(8), 799-813.*

14. *Newman, A. H., Blaylock, B. L., Nader, M. A., Bergman, J., Sibley, D. R., & Skolnick, P. (2012). Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. Biochemical pharmacology, 84(7), 882-890.*

15. *Torrisi, S. A., Geraci, F., Contarini, G., Salomone, S., Drago, F., & Leggio, G. M. (2022). Dopamine D3 receptor, cognition and cognitive dysfunctions in neuropsychiatric disorders: from the bench to the bedside. Therapeutic Applications of Dopamine D3 Receptor Function: New Insight After 30 Years Of Research, 133-156.*

16. *Pich, E. M., & Collo, G. (2015). Pharmacological targeting of dopamine D3 receptors: possible clinical applications of selective drugs. European Neuropsychopharmacology, 25(9), 1437-1447.*

17. *Yang, P., Knight, W. C., Li, H., Guo, Y., Perlmutter, J. S., Benzinger, T. L., ... & Xu, J. (2021). Dopamine D1+ D3 receptor density may correlate with parkinson disease clinical features. Annals of Clinical and Translational Neurology, 8(1), 224-237.*

18. *Karthivashan, G., Ganesan, P., Park, S. Y., Lee, H. W., & Choi, D. K. (2020). Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: From preclinical to translational studies. Biomaterials, 232, 119704.*

19. *Sokoloff, P., & Le Foll, B. (2017). The dopamine D3 receptor, a quarter century later. European Journal of Neuroscience, 45(1), 2-19.*